On Jan. 13, 2026, BriaCell Therapeutics announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell’s personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative.

The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures, achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response, initially observed at 2 months, was subsequently confirmed at 4 months, 6 months, and now at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.

The Phase 1 dose escalation portion of the study is complete and the Phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor, is now underway.

Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and checkpoint inhibitor combination dose expansion cohorts. The Company has recently entered the dose expansion phase.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.